SeQuent Scientific is currently trading at Rs. 173.00, up by 3.10 points or 1.82% from its previous closing of Rs. 169.90 on the BSE.
The scrip opened at Rs. 174.80 and has touched a high and low of Rs. 174.80 and Rs. 164.80 respectively. So far 41621 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 177.25 on 08-Dec-2020 and a 52 week low of Rs. 52.00 on 19-Mar-2020.
Last one week high and low of the scrip stood at Rs. 177.25 and Rs. 158.50 respectively. The current market cap of the company is Rs. 4295.58 crore.
The promoters holding in the company stood at 54.51%, while Institutions and Non-Institutions held 13.12% and 32.37% respectively.
SeQuent Scientific (SeQuent), has launched Citramox LA 150 mg/ml Suspension Injection for Cattle and Pigs in 10 European countries, including the key markets of Western Europe. The product has recently received approval through its Spanish subsidiary Laboratorios Karizoo, S.A., and will be the first Long-Acting injectable to be offered by SeQuent in Europe.
This new approval for SeQuent builds on the recent approvals of Tulazzin (Tulathromycin) and Halofusol (Halofuginone) in Europe. All these approvals have been received within 12 months of filing, which reflects on SeQuent’s growing strengths in introducing new products for the regulated markets.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |